CTRC-AACR SABCS Annual Meeting

SWOG: Two Hormonal Agents Extend Survival over Anastrozole Alone in Metastatic Breast Cancer

By Caroline Helwick

CTRC-AACR SABCS Annual Meeting

December 2011, Vol 2, No 7

;Two antiestrogen agents may be better than one in the treatment of metastatic hormone receptor-positive breast cancer patients, according to a study conducted by the Southwest Oncology Group (SWOG) clinical trials network and presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

New Prognostic Tool to Guide Treatment of Ductal Carcinoma In Situ

By Caroline Helwick

CTRC-AACR SABCS Annual Meeting

December 2011, Vol 2, No 7

Adding Everolimus to Exemestane Significantly Prolongs Remission in Patients with Breast Cancer

By Caroline Helwick

CTRC-AACR SABCS Annual Meeting

December 2011, Vol 2, No 7

Role of Adjuvant Zoledronic Acid in Endocrine Receptor-Positive Breast Cancer Being Refined

By Phoebe Starr

CTRC-AACR SABCS Annual Meeting

December 2011, Vol 2, No 7

Dual HER2 Blockade with Pertuzumab Substantially Delays Disease Progression

By Caroline Helwick

CTRC-AACR SABCS Annual Meeting

December 2011, Vol 2, No 7

San Antonio, TX—It is becoming increasingly clear that 2 agents are better than 1 in treating HER2-positive advanced breast cancer.